Radiation-induced disorder
diseaseOn this page
Also known as abnormalities, radiation inducedAbnormality, radiation-inducedradiation induced abnormalitiesradiation-induced abnormalitiesradiation-induced Abnormality
Summary
Radiation-induced disorder (MONDO:0043459) is a disease (an umbrella term covering 8 Mondo subtypes) with 177 GWAS associations across 17 studies and 7 clinical trials. Top therapeutic interventions include acetaminophen and hydrocodone. A subtype of disease of primarily extrinsic mechanism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 8 Mondo subtypes
- GWAS associations: 177
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | radiation-induced disorder |
| Mondo ID | MONDO:0043459 |
| EFO | EFO:0009565 |
| MeSH | D000016 |
| Orphanet | 521132 |
| NCIT | C26684 |
| SNOMED CT | 85983004 |
| UMLS | C1527225 |
| MedGen | 734320 |
| GARD | 0022139 |
| Is cancer (heuristic) | no |
Also known as: abnormalities, radiation induced · Abnormality, radiation-induced · radiation induced abnormalities · radiation-induced abnormalities · radiation-induced Abnormality · radiation-induced disorder
Data availability: 177 GWAS associations (17 studies).
Disease family
An umbrella term covering 8 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › radiation-induced disorder
Related subtypes (6): infectious disease, post-infectious disorder, poisoning, iatrogenic disease, occupational disorder, disease related to transplantation
Subtypes (8): photokeratitis, photosensitive trichothiodystrophy, photosensitive epilepsy, radiation proctitis, osteoradionecrosis, radiodermatitis, radiation pneumonitis, radiation-induced neuropathy
Genetics & variants
GWAS landscape
177 GWAS associations across 17 studies. Top hits map to 27 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs77658130 | 5e-08 | HULC | A | 0.2 |
| rs141807443 | 1e-07 | MAP3K7 | G | 0.44 |
| rs1592907 | 2e-07 | RN7SL782P - RN7SKP122 | A | 0.13 |
| rs139659427 | 2e-07 | PTPRD | A | 0.3 |
| rs9521025 | 2e-07 | MYO16 | C | 0.2 |
| rs113548225 | 2e-07 | THRAP3P1 - STT3B | A | 0.16 |
| rs142667902 | 2e-07 | DPPA4 - RLIG1P2 | A | 0.17 |
| rs75934032 | 2e-07 | LINC01205 | T | 0.17 |
| rs77008649 | 2e-07 | LINC01808 - CISD1P1 | A | 0.37 |
| rs111794065 | 2e-07 | HAR1A - MIR124-3 | A | 0.16 |
| rs137992872 | 2e-07 | TCF20 | A | 0.21 |
| rs74132977 | 2e-07 | SVIL2P | A | 0.31 |
| rs117387753 | 3e-07 | MUC12 | A | 0.33 |
| rs182358431 | 4e-07 | ATP6V1G1P7 - RPL7P45 | G | 0.46 |
| rs149384519 | 4e-07 | MIR4418 - PPIAP34 | C | 0.59 |
| rs73047089 | 5e-07 | NAALADL2 | A | 0.09 |
| rs79313243 | 5e-07 | SLC35B3 | T | 0.28 |
| rs4785974 | 6e-07 | ZNF500 | C | 0.13 |
| rs146631243 | 6e-07 | LINC02439 - SRRM4 | G | 0.54 |
| rs10107625 | 7e-07 | DLC1 | T | 0.14 |
| rs189583044 | 7e-07 | RNA5SP258 - PPP2R2A | T | 0.57 |
| rs12263252 | 8e-07 | ADRA2A - BTBD7P2 | T | 0.09 |
| rs9959128 | 8e-07 | LINC02565 - RNU6-737P | T | 0.33 |
| rs115881766 | 9e-07 | NUCKS1 - RAB29 | T | 0.21 |
| rs28537315 | 9e-07 | PDLIM5 - BMPR1B-DT | A | 0.29 |
| rs55785618 | 9e-07 | RNU6-996P - RNU6-1064P | T | 0.06 |
| rs73200644 | 9e-07 | MORC1 | C | 0.17 |
| rs36167665 | 9e-07 | LINC00887 - CPN2 | G | 0.11 |
| rs7207494 | 9e-07 | HS3ST3A1 | C | 0.12 |
| rs3857066 | 1e-06 | GRID2 | G | 0.12 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90080355 | Backman JD | 2021 | 7,797 | 370,171 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084341 | Backman JD | 2021 | 7,797 | 370,171 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90727041 | Kim HI | 2026 | 465 | 43,561 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90435416 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90435417 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90444377 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90444378 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90444379 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90444380 | Naderi E | 2023 | 0 | 0 | Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. |
| GCST90095192 | Naderi E | 2021 | 0 | 0 | A two-stage genome-wide association study of radiation-induced acute toxicity in head and neck cancer. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 3 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 46 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 33 |
| low_freq (0.01-0.05) | 13 |
| rare (<0.01) | 0 |
| unknown | 4 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 30 |
| intergenic_variant | 13 |
| 3_prime_UTR_variant | 3 |
| non_coding_transcript_exon_variant | 3 |
| missense_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs77658130 | 6 | 8837005 | G>A,T | 0.04 | intergenic_variant | HULC | 5e-08 | Tier 4: intronic/intergenic |
| rs141807443 | 6 | 90514792 | A>G | 3_prime_UTR_variant | MAP3K7 | 1e-07 | Tier 2: splice/UTR | |
| rs1592907 | 5 | 107767862 | A>G,T | 0.05 | intergenic_variant | RN7SL782P - RN7SKP122 | 2e-07 | Tier 4: intronic/intergenic |
| rs139659427 | 9 | 9370004 | G>A,T | 0.05 | intron_variant | PTPRD | 2e-07 | Tier 4: intronic/intergenic |
| rs9521025 | 13 | 108769778 | A>C | 0.05 | intron_variant | MYO16 | 2e-07 | Tier 4: intronic/intergenic |
| rs113548225 | 3 | 31510706 | T>A | 0.048 | intron_variant | THRAP3P1 - STT3B | 2e-07 | Tier 4: intronic/intergenic |
| rs142667902 | 3 | 109354688 | G>A | 0.031 | intron_variant | DPPA4 - RLIG1P2 | 2e-07 | Tier 4: intronic/intergenic |
| rs75934032 | 3 | 109464005 | C>T | 0.031 | intron_variant | LINC01205 | 2e-07 | Tier 4: intronic/intergenic |
| rs77008649 | 2 | 19604237 | G>A,T | 0.012 | intron_variant | LINC01808 - CISD1P1 | 2e-07 | Tier 4: intronic/intergenic |
| rs111794065 | 20 | 63177878 | G>A,C | 0.118 | intron_variant | HAR1A - MIR124-3 | 2e-07 | Tier 4: intronic/intergenic |
| rs137992872 | 22 | 42246837 | G>A,T | 0.069 | intron_variant | TCF20 | 2e-07 | Tier 4: intronic/intergenic |
| rs74132977 | 10 | 30682334 | G>A | 0.054 | intron_variant | SVIL2P | 2e-07 | Tier 4: intronic/intergenic |
| rs117387753 | 7 | 100991606 | G>A,C,T | missense_variant | MUC12 | 3e-07 | Tier 1: coding | |
| rs182358431 | 13 | 104319886 | A>G | 0.05 | intergenic_variant | ATP6V1G1P7 - RPL7P45 | 4e-07 | Tier 4: intronic/intergenic |
| rs149384519 | 1 | 22307683 | T>C | intron_variant | MIR4418 - PPIAP34 | 4e-07 | Tier 4: intronic/intergenic | |
| rs73047089 | 3 | 174956020 | G>A | 0.079 | intron_variant | NAALADL2 | 5e-07 | Tier 4: intronic/intergenic |
| rs79313243 | 6 | 8412720 | C>T | 0.023 | 3_prime_UTR_variant | SLC35B3 | 5e-07 | Tier 2: splice/UTR |
| rs4785974 | 16 | 4754650 | C>A,G,T | 0.05 | intron_variant | ZNF500 | 6e-07 | Tier 4: intronic/intergenic |
| rs146631243 | 12 | 118962551 | A>G | intergenic_variant | LINC02439 - SRRM4 | 6e-07 | Tier 4: intronic/intergenic | |
| rs10107625 | 8 | 13324521 | C>A,G,T | 0.05 | intron_variant | DLC1 | 7e-07 | Tier 4: intronic/intergenic |
| rs189583044 | 8 | 26270368 | C>G,T | 0.05 | intron_variant | RNA5SP258 - PPP2R2A | 7e-07 | Tier 4: intronic/intergenic |
| rs12263252 | 10 | 111282068 | C>T | 0.066 | intergenic_variant | ADRA2A - BTBD7P2 | 8e-07 | Tier 4: intronic/intergenic |
| rs9959128 | 18 | 57280264 | G>T | 0.064 | intron_variant | LINC02565 - RNU6-737P | 8e-07 | Tier 4: intronic/intergenic |
| rs115881766 | 1 | 205761677 | C>T | 0.05 | intergenic_variant | NUCKS1 - RAB29 | 9e-07 | Tier 4: intronic/intergenic |
| rs28537315 | 4 | 94680078 | G>A | 0.05 | intron_variant | PDLIM5 - BMPR1B-DT | 9e-07 | Tier 4: intronic/intergenic |
| rs55785618 | 9 | 107710615 | A>G,T | 0.171 | intergenic_variant | RNU6-996P - RNU6-1064P | 9e-07 | Tier 4: intronic/intergenic |
| rs73200644 | 3 | 108958348 | T>C | 0.024 | 3_prime_UTR_variant | MORC1 | 9e-07 | Tier 2: splice/UTR |
| rs36167665 | 3 | 194331825 | A>C,G,T | 0.349 | intergenic_variant | LINC00887 - CPN2 | 9e-07 | Tier 4: intronic/intergenic |
| rs7207494 | 17 | 13514792 | T>C | 0.215 | intron_variant | HS3ST3A1 | 9e-07 | Tier 4: intronic/intergenic |
| rs3857066 | 4 | 93494363 | A>C,G,T | 0.05 | intron_variant | GRID2 | 1e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02480114 | PHASE3 | COMPLETED | Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy |
| NCT00741754 | PHASE2 | COMPLETED | Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use HcT20 |
| NCT04676828 | Not specified | RECRUITING | Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer |
| NCT06816095 | Not specified | RECRUITING | Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment |
| NCT00388713 | Not specified | UNKNOWN | Radiation Induced Atherosclerosis in Breast Cancer Patients |
| NCT00652678 | Not specified | TERMINATED | Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients |
| NCT01692600 | Not specified | COMPLETED | Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ACETAMINOPHEN | 4 | 1 |
| HYDROCODONE | 4 | 1 |
Related Atlas pages
- Drugs: Acetaminophen, Hydrocodone